Erratum: Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status (British Journal of Cancer, (1998), 77, 11, (1761-1767), 10.1038/bjc.1998.294);Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1761-1767

  Beauregard, D A ^a   Thelwall, P E ^a   Chaplin, D J ^b   Hill, S A ^b   Adams, G E ^b   Brindle, K M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

31P spectroscopy; Combretastatin A4; GdDTPA; Haemorrhage; Magnetic resonance imaging; Tumour perfusion

Indexed keywords

COMBRETASTATIN A4; GADOLINIUM PENTETATE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CELL ENERGY; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; ENERGY TRANSFER; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PH; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SPECTROSCOPY; TISSUE SECTION; TUMOR VASCULARIZATION;

EID: 0031748452     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1998.590     Document Type: Erratum

References (20)

1. Bhujwalla ZM, Shungu DC, He Q, Wehrle JP and Glickson JD (1994) MR studies of tumours: relationship between blood flow, metabolism, and physiology. In NMR in Physiology and Biomedicine, Gillies RJ (ed), pp. 311-328. Academic Press: San Diego
2. Brooks RA and Di Chiro G (1987) Magnetic resonance imaging of stationary blood: a review. Med Phys 14:903-913
3. Chaplin DJ, Pettit GR, Parkins CS and Hill SA (1996) Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer 74: S86-S88
4. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834
5. Denekamp J, Hill SA and Hobson B (1983) Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19: 271-275
6. 2 in a RIF-1 tumor. Magn Reson Med 34: 515-519
7. 31P NMR. Magn Reson Med 18: 181-192
8. 31P nuclear magnetic resonance. Nature 252: 285-287
9. Kennedy SD, Szczepaniak LS, Gibson SL, Hilf R, Foster TH and Bryant RG (1994) Quantitative MRI of Gd-DTPA uptake in tumours: response to photodynamic therapy. Magn Reson Med 31: 292-301
10. Latour LL, Svoboda K, Mitra PP and Sotak CH (1994) Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci USA 91: 1229-1233
11. Maier CF, Paran Y, Bendel P, Rutt BK and Degani H (1997) Quantitative diffusion imaging in implanted human breast tumors. Magn Reson Med 37: 576-581
12. Negendank W (1992) Studies of human tumours by MRS: A review. NMR Biomed 5: 303-324
13. Ordidge RJ, Connelly A and Lohman JAB (1986) Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 66: 283-294
14. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 115-211
15. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA and Bansal N (1995) Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Design 10: 299-309
16. 31P nuclear magnetic resonance spectroscopy: A review. NMR Biomed 49: 4075-4085
17. Stejskal EO, Tanner JE (1965) Spin diffusion measurements: spin echoes in the presence of a lime-dependent field gradient. J Chem Phys 42: 288-292
18. 31P MRS as a method of measuring pH in rat tumours. NMR Biomed 5: 351-359
19. 31P nuclear magnetic resonance study. Mol Biol Med 1: 77-94
20. 31P MRS observations of tumour energy metabolism. NMR Biomed 5: 279-289